Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 27, 2019 in Prostate cancer | 0 comments

In a nutshell

This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients.

Some background

One treatment option for patients with prostate cancer is androgen deprivation therapy (ADT). This treatment blocks the production of male hormones like testosterone responsible for cancer growth. However, some patients stop responding to this treatment. This is called castration-resistant prostate cancer (CRPC).

Adding apalutamide to ADT has been shown to reduce the risk of cancer spread. Apalutamide blocks androgens from taking effect in the body. The effect of apalutamide on overall survival (OS) in patients with CRPC is still unknown. 

Methods & findings

This study included 1207 patients with CRPC treated with ADT. 806 men were treated with apalutamide and ADT. 401 had a placebo added to ADT. Patients were followed up for an average of 41 months.

Apalutamide was associated with a 25% reduction in risk of death compared with placebo. The 4-year survival at 4 years was 72% in the apalutamide group compared to 65% in the placebo group. Apalutamide reduced the risk of disease progression by 45% compared to placebo.

The bottom line

This study found that apalutamide had a positive effect on the survival of patients with castration-resistant prostate cancer. 

Published By :

Annals of oncology: official journal of the European Society for Medical Oncology

Date :

Sep 27, 2019

Original Title :

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.

click here to get personalized updates